Month: March 2023

Viewbix is a subsidiary of Gix Internet whose results are consolidated with Medigus’ financial statements Tel Aviv, Israel, March 27, 2023 (GLOBE NEWSWIRE) —  Medigus Ltd. (Nasdaq: MDGS), a technology company engaged in advanced medical solutions, innovative internet technologies and electric vehicle and charging solutions, announced today that Viewbix Inc. (henceforth “Viewbix”) (OTC: VBIX), 76% owned by Medigus’ subsidiary Gix Internet, (henceforth “Gix”) (42.25% owned by Medigus) (TASE: GIX), a global marketing technology (MarTech) solutions company for online performance-based-marketing, reported its financial results for the fourth quarter and the fiscal year ended December 31, 2022. Key highlights for the fourth quarter and the fiscal year ended December 31, 2022, include:Revenues for the fiscal year ended December 31,...

TORONTO, March 27, 2023 (GLOBE NEWSWIRE) — Skyline Investments Inc. (the “Company” or “Skyline”) (TASE: SKLN), a Canadian company that specializes in hotel real estate investments in the United States and Canada, published its results for the year ended December 31, 2022. SUMMARY OF FINANCIAL RESULTSC$000’s 2022   2021   2020  NOI1 from Hotels & Resorts 27,535   33,081   11,359  NOI from Hotels & Resorts Margin 21%   26%   12%  Same Asset Revenue 129,287   90,150   55,207  Same Asset NOI1 25,904   22,184   3,392  Same Asset NOI Margin 20%   25%   6%  Adjusted EBITDA2 19,727   24,501   7,884  Adjusted EBITDA Margin 15%   18%   6%  Net Income (loss) (2,025)   29,578   (18,637)  FFO1 9,285   12,312   (3,761)  Shareholders’ Equity 280,458   266,249   226,044  Q4 and 2022 Highlights2022...

Signed Strategic Collaboration Agreement with Lantheus Holdings Inc. for POINT’s PNT2002 and PNT2003 product candidates Completed enrollment for randomization phase of PNT2002’s phase 3 SPLASH registrational trial, with top line data expected in the second half of 2023 INDIANAPOLIS, March 27, 2023 (GLOBE NEWSWIRE) — POINT Biopharma Global Inc. (NASDAQ: PNT) (the “Company” or “POINT”), a company accelerating the discovery, development, and global access to life-changing radiopharmaceuticals, today announced financial results for the fourth quarter and full year ended December 31, 2022 and provided a business update. “POINT continued to make significant progress in 2022, enabled by our company’s deep expertise in radioligands and our vertically integrated, highly differentiated radioligand platform,” said Joe McCann,...

A total of 8,543 hotels or 809,478 hotel rooms in operation as of December 31, 2022. Hotel turnover1 increased 10.5% year-over-year to RMB13.1 billion in the fourth quarter of 2022, and increased 9.3% year-over-year to RMB49.6 billion for the full year of 2022. Excluding Steigenberger Hotels GmbH and its subsidiaries (“DH”, or “Legacy-DH”), hotel turnover increased 5.3% year-over-year in the fourth quarter of 2022 and increased 3.5% year-over-year for the full year of 2022. Revenue increased 10.7% year-over-year to RMB3.7 billion (US$537 million)2 in the fourth quarter of 2022, in line with the revenue guidance previously announced of a 7% to 11% increase compared to the fourth quarter of 2021, and increased 8.4% year-over-year to RMB13.9 billion (US$2.0 billion) for the full year of 2022. Revenue from the Legacy-Huazhu segment in the...

IRVINE, Calif., March 27, 2023 (GLOBE NEWSWIRE) — Reneo Pharmaceuticals, Inc. (Nasdaq: RPHM), a clinical-stage pharmaceutical company focused on the development and commercialization of therapies for patients with rare genetic mitochondrial diseases, today reported financial results for the quarter and year ended December 31, 2022 and provided a business update. 2022 and Recent HighlightsAchieved the target enrollment of 200 patients in the pivotal STRIDE study of mavodelpar (REN001) in adult patients with primary mitochondrial myopathies (PMM); topline results anticipated in the fourth quarter of 2023 Enrolled 85% of eligible STRIDE study patients in the STRIDE AHEAD study, the mavodelpar long-term safety clinical trial in adult patients with PMM Received confirmation from the U.S. Food and Drug Administration (FDA) and European...

CHERRY HILL, N.J., March 27, 2023 (GLOBE NEWSWIRE) — The Real Good Food Company, Inc. (NASDAQ: RGF) (“Real Good Foods” or the “Company”), a leading health and wellness frozen foods company, today reported financial results for its fourth quarter and fiscal year ended December 31, 2022. Management Commentary Bryan Freeman, Executive Chairman, said: “The fourth quarter was reflective of the growing strength of our brand, helping to meet increasing demand for healthier frozen food options with innovative new products such as our Breaded Poultry, Breakfast Flautas and Creamy Poblano Enchiladas. While sales came in below our original expectations, this was driven by the strategic dialing back of promotional expenses on a non-core product in the unmeasured channel that would have diluted margins. Moreover, our distribution gains are...

CAPE CANAVERAL, Fla., March 27, 2023 (GLOBE NEWSWIRE) — Vaxxinity, Inc. (Nasdaq: VAXX), a U.S. company pioneering the development of a new class of immunotherapeutic vaccines, today reported financial results for the fourth quarter and full year ended December 31, 2022. “We are grateful for and proud of our accomplishments in our first full year as a public company, and remain on track to continue to hit our milestones in 2023 as we pursue our greater mission of democratizing health with our innovative vaccine technology,” said Mei Mei Hu, CEO of Vaxxinity. “This year, we are poised to achieve our first potential marketing authorization as a company with UB-612, a heterologous booster vaccine candidate for COVID-19. We also expect to see two potential clinical proofs-of-concept in chronic disease in our migraine and hypercholesterolemia...